Lilly Just Paid $2.75B for a Robot's Homework

Eli Lilly gains exclusive rights to AI-discovered drug candidates in a deal worth up to $2.75B with Insilico Medicine

31 Mar 2026

Eli Lilly has agreed to pay up to $2.75 billion for exclusive worldwide rights to a portfolio of drug candidates designed entirely by artificial intelligence, in one of the largest transactions yet to test whether machine-generated molecules can be turned into approved medicines.

Under terms announced with Insilico Medicine, a Hong Kong-listed biotech, Lilly will receive rights to a pipeline of novel oral compounds produced by Insilico's generative AI platform. The company will also pay $115 million upfront, with the balance tied to development, regulatory, and commercial milestones, plus tiered royalties on future sales. The two companies will also expand their relationship through new joint research programs targeting disease areas of particular interest to Lilly.

At the center of the agreement is Insilico's Pharma.AI platform, which approaches drug discovery differently from conventional methods. Rather than screening libraries of existing compounds, the system designs new molecules from the ground up, identifying disease targets, generating candidate structures, and modeling clinical behavior before any laboratory synthesis begins. According to company statements, the platform has generated at least 28 drug candidates, with nearly half already in clinical testing.

For Lilly, the attraction is competitive speed. Drug discovery remains costly and slow, and AI-generated pipelines offer a faster path to novel therapeutics across several disease categories. The companies first worked together in 2023 under a software licensing arrangement; this deal converts that early collaboration into a full commercialization commitment.

Still, the transaction carries meaningful uncertainty. AI-designed molecules have yet to clear the clinical and regulatory hurdles that remain the primary test of any new drug. The size of the deal reflects industry confidence in the approach, analysts have noted, but milestone-heavy structures also allow large acquirers to limit exposure if early candidates fail. Whether Insilico's compounds perform in late-stage trials will ultimately determine whether this deal represents an inflection point for AI-driven discovery or a costly bet on a maturing but still unproven technology. Those results could shape how the broader pharmaceutical industry allocates its research investment for years ahead.